Cargando…

Muscle and serum myostatin expression in type 1 diabetes

Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle‐wasting diseases, has not been reported in humans with T1D but has been demonstrated to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dial, Athan G., Monaco, Cynthia M. F., Grafham, Grace K., Romanova, Nadya, Simpson, Jeremy A., Tarnopolsky, Mark A., Perry, Christopher G. R., Kalaitzoglou, Evangelia, Hawke, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354085/
https://www.ncbi.nlm.nih.gov/pubmed/32652899
http://dx.doi.org/10.14814/phy2.14500
_version_ 1783558011118157824
author Dial, Athan G.
Monaco, Cynthia M. F.
Grafham, Grace K.
Romanova, Nadya
Simpson, Jeremy A.
Tarnopolsky, Mark A.
Perry, Christopher G. R.
Kalaitzoglou, Evangelia
Hawke, Thomas J.
author_facet Dial, Athan G.
Monaco, Cynthia M. F.
Grafham, Grace K.
Romanova, Nadya
Simpson, Jeremy A.
Tarnopolsky, Mark A.
Perry, Christopher G. R.
Kalaitzoglou, Evangelia
Hawke, Thomas J.
author_sort Dial, Athan G.
collection PubMed
description Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle‐wasting diseases, has not been reported in humans with T1D but has been demonstrated to be elevated in preclinical diabetes models. Thus, the purpose of this study was to determine if there is an elevated expression of myostatin in the serum and skeletal muscle of persons with T1D compared to controls. Secondarily, we aimed to explore relationships between myostatin expression and clinically important metrics (e.g., HbA(1c), strength, lean mass) in women and men with (N = 31)/without T1D (N = 24) between 18 and 72 years old. Body composition, baseline strength, blood sample and vastus lateralis muscle biopsy were evaluated. Serum, but not muscle, myostatin expression was significantly elevated in those with T1D versus controls, and to a greater degree in T1D women than T1D men. Serum myostatin levels were not significantly associated with HbA(1c) nor disease duration. A significant correlation between serum myostatin expression and maximal voluntary contraction (MVC) and body fat mass was demonstrated in control subjects, but these correlations did not reach significance in those with T1D (MVC: R = 0.64 controls vs. R = 0.37 T1D; Body fat: R = −0.52 controls/R = −0.02 T1D). Collectively, serum myostatin was correlated with lean mass (R = 0.45), and while this trend was noted in both groups separately, neither reached statistical significance (R = 0.47 controls/R = 0.33 T1D). Overall, while those with T1D exhibited elevated serum myostatin levels (particularly females) myostatin expression was not correlated with clinically relevant metrics despite some of these relationships existing in controls (e.g., lean/fat mass). Future studies will be needed to fully understand the mechanisms underlying increased myostatin in T1D, with relationships to insulin dosing being particularly important to elucidate.
format Online
Article
Text
id pubmed-7354085
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73540852020-07-17 Muscle and serum myostatin expression in type 1 diabetes Dial, Athan G. Monaco, Cynthia M. F. Grafham, Grace K. Romanova, Nadya Simpson, Jeremy A. Tarnopolsky, Mark A. Perry, Christopher G. R. Kalaitzoglou, Evangelia Hawke, Thomas J. Physiol Rep Original Research Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle‐wasting diseases, has not been reported in humans with T1D but has been demonstrated to be elevated in preclinical diabetes models. Thus, the purpose of this study was to determine if there is an elevated expression of myostatin in the serum and skeletal muscle of persons with T1D compared to controls. Secondarily, we aimed to explore relationships between myostatin expression and clinically important metrics (e.g., HbA(1c), strength, lean mass) in women and men with (N = 31)/without T1D (N = 24) between 18 and 72 years old. Body composition, baseline strength, blood sample and vastus lateralis muscle biopsy were evaluated. Serum, but not muscle, myostatin expression was significantly elevated in those with T1D versus controls, and to a greater degree in T1D women than T1D men. Serum myostatin levels were not significantly associated with HbA(1c) nor disease duration. A significant correlation between serum myostatin expression and maximal voluntary contraction (MVC) and body fat mass was demonstrated in control subjects, but these correlations did not reach significance in those with T1D (MVC: R = 0.64 controls vs. R = 0.37 T1D; Body fat: R = −0.52 controls/R = −0.02 T1D). Collectively, serum myostatin was correlated with lean mass (R = 0.45), and while this trend was noted in both groups separately, neither reached statistical significance (R = 0.47 controls/R = 0.33 T1D). Overall, while those with T1D exhibited elevated serum myostatin levels (particularly females) myostatin expression was not correlated with clinically relevant metrics despite some of these relationships existing in controls (e.g., lean/fat mass). Future studies will be needed to fully understand the mechanisms underlying increased myostatin in T1D, with relationships to insulin dosing being particularly important to elucidate. John Wiley and Sons Inc. 2020-07-11 /pmc/articles/PMC7354085/ /pubmed/32652899 http://dx.doi.org/10.14814/phy2.14500 Text en © 2020 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Dial, Athan G.
Monaco, Cynthia M. F.
Grafham, Grace K.
Romanova, Nadya
Simpson, Jeremy A.
Tarnopolsky, Mark A.
Perry, Christopher G. R.
Kalaitzoglou, Evangelia
Hawke, Thomas J.
Muscle and serum myostatin expression in type 1 diabetes
title Muscle and serum myostatin expression in type 1 diabetes
title_full Muscle and serum myostatin expression in type 1 diabetes
title_fullStr Muscle and serum myostatin expression in type 1 diabetes
title_full_unstemmed Muscle and serum myostatin expression in type 1 diabetes
title_short Muscle and serum myostatin expression in type 1 diabetes
title_sort muscle and serum myostatin expression in type 1 diabetes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354085/
https://www.ncbi.nlm.nih.gov/pubmed/32652899
http://dx.doi.org/10.14814/phy2.14500
work_keys_str_mv AT dialathang muscleandserummyostatinexpressionintype1diabetes
AT monacocynthiamf muscleandserummyostatinexpressionintype1diabetes
AT grafhamgracek muscleandserummyostatinexpressionintype1diabetes
AT romanovanadya muscleandserummyostatinexpressionintype1diabetes
AT simpsonjeremya muscleandserummyostatinexpressionintype1diabetes
AT tarnopolskymarka muscleandserummyostatinexpressionintype1diabetes
AT perrychristophergr muscleandserummyostatinexpressionintype1diabetes
AT kalaitzoglouevangelia muscleandserummyostatinexpressionintype1diabetes
AT hawkethomasj muscleandserummyostatinexpressionintype1diabetes